Background: A number of studies have shown poorer survival among cancer patients with comorbidity. Several mechanisms may underlie this finding. In this review we summarize the current literature on the association between patient comorbidity and cancer prognosis. Prognostic factors examined include tumor biology, diagnosis, treatment, clinical quality, and adherence. Methods: All English-language articles published during 2002-2012 on the association between comorbidity and survival among patients with colon cancer, breast cancer, and lung cancer were identified from PubMed, MEDLINE and Embase. Titles and abstracts were reviewed to identify eligible studies and their main results were then extracted. Results: Our search yielded more than 2,500 articles related to comorbidity and cancer, but few investigated the prognostic impact of comorbidity as a primary aim. Most studies found that cancer patients with comorbidity had poorer survival than those without comorbidity, with 5-year mortality hazard ratios ranging from 1.1 to 5.8. Few studies examined the influence of specific chronic conditions. In general, comorbidity does not appear to be associated with more aggressive types of cancer or other differences in tumor biology. Presence of specific severe comorbidities or psychiatric disorders were found to be associated with delayed cancer diagnosis in some studies, while chronic diseases requiring regular medical visits were associated with earlier cancer detection in others. Another finding was that patients with comorbidity do not receive standard cancer treatments such as surgery, chemotherapy, and radiation therapy as often as patients without comorbidity, and their chance of completing a course of cancer treatment is lower. Postoperative complications and mortality are higher in patients with comorbidity. It is unclear from the literature whether the apparent undertreatment reflects appropriate consideration of greater toxicity risk, poorer clinical quality, patient preferences, or poor adherence among patients with comorbidity. Conclusion: Despite increasing recognition of the importance of comorbid illnesses among cancer patients, major challenges remain. Both treatment effectiveness and compliance appear compromised among cancer patients with comorbidity. Data on clinical quality is limited.
Introduction
It is essential to personalized medicine to understand how patient characteristics such as age and coexisting diseases (comorbidity) affect cancer detection, treatment, and outcome. With more than 60% of cancer patients diagnosed at age 65 or older in high-income countries, 1 many patients have comorbidities that complicate the decision-making process. Because the elderly and persons with comorbidity are often underrepresented in clinical trials, 2, 3 information regarding treatment effectiveness is often extrapolated from studies of younger patients without comorbidity. Several studies have shown poorer survival among cancer patients with comorbidity, [4] [5] [6] [7] [8] [9] [10] [11] but the underlying mechanisms remain unclear. In recent decades 5-year survival rates have improved among cancer patients without comorbidity, but not among patients with severe comorbidity. [4] [5] [6] An understanding of how comorbidity affects survival in patients with cancer is needed to guide clinical practice. We therefore reviewed the literature on the association between comorbidity and survival among patients with three of the most commonly diagnosed cancers: colon cancer, breast cancer, and lung cancer.
Methods

Definition and measurement of comorbidity
Comorbidity has been defined as "any additional clinical entity that has existed or that may occur during the clinical course of a patient with an index disease under study." 12, 13 The term "multimorbidity" is often used interchangeably with "comorbidity" but has a slightly different meaning. Multimorbidity refers to the coexistence of $2 illnesses without identifying an index disease.
14 Comorbidity must also be distinguished from complications that arise as a consequence of the cancer or its treatment. A number of studies have examined the prognostic impact of patients' "performance status" at the time of cancer diagnosis. Performance status is a measure of a cancer patient's wellbeing defined as the amount of normal daily activity the patient can maintain. [15] [16] [17] However, performance status is affected by cancer, complications of cancer, and comorbid conditions. 18 Therefore, measures of comorbidity must be distinguished from measures of performance status.
Data on comorbid diseases are available from different data sources, such as medical records, administrative databases, physical examinations, and self-reports using questionnaires. [19] [20] [21] Comorbidity can be assessed by counting the number of coexisting diseases diagnosed in a cancer patient or by using a comorbidity index that combines the number and severity of the diseases. The most widely used index is the Charlson Comorbidity Index (CCI). The original Charlson measure was constructed to predict 1-year mortality in 559 medical patients as well as 10-year mortality rates for death attributable to comorbid diseases among 685 breast cancer patients. 22 The index is based on 19 distinct medical disease categories. Each condition has a weight assigned from 1 to 6, derived from the relative risk estimates obtained from a regression model. The CCI score is the sum of weights for all prevalent conditions. The score can theoretically range from 0-33 but was collapsed into categories of 0, 1-2, 3-4, and $5 in its initial presentation. 22, 23 Literature search
We searched PubMed, MEDLINE and Embase to identify and summarize existing information on the association between comorbidity and cancer survival in patients with colon cancer, breast cancer, and lung cancer. We used the following keywords to identify potentially useful articles: "comorbidity," "multimorbidity," and "coexisting diseases." In addition, we searched for articles on the following prevalent comorbid diseases: diabetes, cardiovascular diseases, chronic pulmonary disease, and dementia. Furthermore, we queried the databases using the terms "colon cancer," "breast cancer," "lung cancer," and "comorbidity" combined with such terms as "pathogenesis," "histology," "differentiation," "stage," "diagnosis," "centralized treatment," "specialized treatment," "patient volume," and "surgeon volume." We limited our search to English-language articles published within the last 10 years. All searches were performed at the end of November 2012. Our PubMed search strategy is described in detail in Table S1 .
Overall, we identified 2,692 potentially eligible articles ( Figure 1 ). The first author (MS) reviewed the titles and abstracts and removed articles not relevant to comorbidity and cancer survival. The information summarized in this review was gleaned from the remaining articles and prior publications cited by these articles.
As average life expectancy increases in Western countries, the proportion of elderly cancer patients also is expected to increase. 25 Because the prevalence of comorbidity increases with age, the number of cancer patients with comorbidity will increase concomitantly. This is indicated in a US study of 49,646 women aged 67 years or older with breast cancer in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data set. Among these patients, 23% of women aged 85-89 years and 11.2% of women aged 67-69 years had severe comorbidity. 26 In a study from The Netherlands, 53% of patients aged 60-74 years were found to have at least one comorbidity, and this proportion increased to 63% in patients aged 75 years and older. 24 
Impact of comorbidity on cancer survival
Most observational studies have found that cancer patients with comorbidities have poorer survival than patients without comorbidities. [4] [5] [6] [7] [8] [9] [10] [11] 24, [28] [29] [30] Cohort studies with 5-7 years of follow-up have reported 1.1-to 5.8-fold higher mortality for breast cancer patients with any comorbidity compared to patients with no comorbidity. 4, 20, 26, 31, 32 Similarly, studies of patients with colon cancer have reported 1.2-to 4.8-fold higher 5-year mortality for patients with comorbidity versus without comorbidity. 5, 8, 9, 25, 32, 34 Correspondingly, mortality in patients with lung cancer is 1.1 to 1.5 times higher for patients with comorbidity in studies with 1-5 years of follow-up. 7, 29, 34, 35 Not surprisingly, if survival among patients with a particular type of cancer is generally very poor, the additional effect of comorbid diseases on mortality on a relative scale is small. 34, 36, 37 Thus, the relatively lower prognostic impact of comorbidity among lung cancer patients is probably due to a 1-year mortality rate above 70% even among otherwise healthy patients. 24 Stage at diagnosis influences decisions about the appropriate course of treatment and is strongly associated with cancer survival. Thus, stage-specific analyses may provide more insight into the association between comorbidity and cancer survival. Among A key question is whether the higher mortality observed in cancer patients with comorbidity stems from their comorbidity or whether their cancer-specific mortality is elevated. In a recent Danish cohort study of 6,325 patients aged $70 years with breast, lung, colorectal, prostate, or ovarian cancer, 5-year all-cause mortality increased with higher levels of comorbidity. 24 For 5-year cancer-specific mortality, however, comorbidity was associated with increased rates only in patients with lung cancer (5-year HR for CCI score $3 vs CCI score of 0 = 1.29 [95% CI: 1.03-1.60]). . Several other studies have found an association between increasing levels of comorbidity and higher cancer-related mortality among patients with colon, breast, or lung cancer. 8, 9, 25, [39] [40] [41] However, there is considerable uncertainty in defining whether death was due to the cancer or to other causes (including comorbidity), and the validity of cause-of-death data may be questioned. Effect of comorbidity on survival Comorbidity can affect cancer survival through its impact on such factors as cancer detection, treatment, and adherence. 45 In the following sections, we focus on the potential role of comorbidity on different points from cancer detection through diagnosis and treatment.
Impact of comorbidity on cancer morphology, histology, differentiation, and proliferation status It is plausible that comorbidity is associated with differences in morphology, histology, differentiation, and proliferation status. Cancer risk is elevated in patients with obesity; in patients with diabetes and resulting insulin resistance and chronic hyperinsulinemia; [46] [47] [48] [49] and in patients with inherited, acquired (eg, from HIV/AIDS), or drug-induced (eg, from treatment with steroids or biologics) immunosuppression. 50, 51 Some of these risk factors also may be associated with rate of cancer growth and cancer grade/differentiation and thus with prognosis. Conversely, drugs such as nonsteroidal antiinflammatory agents, 52, 53 aspirin, 54, 55 statins, 56 and long-term antibiotics used to treat comorbidity-associated infections 57 may decrease cancer incidence, [52] [53] [54] [55] progression, 53, 56 and risk of recurrence and improve cancer prognosis. [58] [59] [60] [61] As shown in Table 2 , the proportion of squamous cell carcinoma in lung cancer patients with comorbidity has been found to be 6%-11% higher than in patients without comorbidity. 10, 11 Chlebowski et al 62 found a slightly higher proportion of ductal breast cancer (69% vs 65%) and a slightly lower proportion of estrogen-receptor-positive breast cancer (74% vs 78%) and progesterone-receptorpositive breast cancer (61% vs 64%) among diabetic compared with nondiabetic breast cancer patients (Table 2) . Kaplan et al 63 also found a higher incidence of ductal breast cancer among diabetics compared with nondiabetics (89% vs 82%). In contrast, Land et al 6 found no differences in histology or receptor status according to level of comorbidity. However, few studies provided data on tumor biology by comorbidity level.
Comorbidity and other patient characteristics
Age is closely related to comorbidity and is also a strong predictor of mortality in cancer patients. Thus, older age could potentially explain the prognostic impact of comorbidity. However, the association between comorbidity and cancer survival persists even after adjusting for age. The association also remains after adjusting for other prognostic factors, such as cancer stage and treatment. 64 It is also plausible that age may modify the relationship between comorbidity and cancer survival if clinicians tend to focus more on comorbidity in older than in younger patients when deciding on type of cancer treatment. 65 Sex may also play a role, as several studies have indicated that women with lung cancer have a better prognosis than men with lung cancer. [66] [67] [68] The underlying reasons are debated and remain unresolved. In addition, converging evidence from epidemiological studies conducted in a variety of settings have documented racial and socioeconomic disparities in cancer survival. [67] [68] [69] [70] [71] [72] [73] [74] Multiple factors may contribute to these disparities, but comorbidity seems to play an important role. [72] [73] [74] [75] [76] [77] In a US cohort study of 906 women with breast cancer, Tammemagi et al 78 found an HR for all-cause mortality of 1.14 (95% CI: 0.92-1.40) for blacks compared to whites after adjusting for age, tumor stage, estrogen receptor status, surgery, chemotherapy, and radiation therapy. After further adjustment for comorbidity, the HR decreased to 1.02 (95% CI: 0.83-1.27). The two most important comorbidities explaining the disparities were diabetes and hypertension. 78 A Danish cohort study conducted by Dalton et al 79 found an interaction between income and comorbidity, resulting in 15% lower survival within 10 years after primary surgery for early-stage breast cancer among women of low socioeconomic status with comorbid conditions (∼65%) compared to more affluent women with similar comorbid conditions (∼80%). This suggests a differential effect of comorbidity on risk of dying of early-stage breast cancer by socioeconomic group. 75 
Impact of comorbidity on stage at diagnosis
It is often argued that comorbidities may be associated with late-stage cancer diagnosis because they may mask early cancer symptoms. Dementia, 80, 81 alcohol consumption, 82, 83 and major depression 84 have been associated with late-stage diagnosis of colon cancer and breast cancer. However, as shown in Table 3 , several studies have found a higher prevalence of comorbidity in patients diagnosed with early-stage lung cancer, breast cancer, and colorectal cancer. Earlier cancer diagnosis in patients with comorbidities is plausible because these patients are more likely to require frequent medical care, and hence to receive closer clinical monitoring, than persons without comorbidities. Nonetheless, the association between comorbidity and earlier diagnosis seems to depend on the specific comorbid condition. Fleming et al 85 found that women with cardiovascular disease, musculoskeletal disease, gastrointestinal disease, osteoarthritis, and genitourinary disease had a 7%-24% lower risk of being diagnosed with advanced breast cancer (Table 3 ). In contrast, women with diabetes, renal disease, other endocrine submit your manuscript | www.dovepress.com Table 2 Results of selected studies on the association between comorbidity and cancer characteristics disorders, psychiatric disease, osteoporosis, hematologic disease, obesity, and AIDS had an 11%-20% higher risk of being diagnosed with advanced disease (Table 3) . 85 Similarly, Yasmeen et al 76 found that presence of certain comorbidities (eg, arthritis, depression, diabetes, stable coronary artery disease) was associated with higher utilization of screening mammograms and greater likelihood of diagnosis of localized disease (odds ratio [OR] = 0.8, 95% CI: 0.7-0.9), while a group of other comorbidities judged to be more serious (including severe heart failure, cardiac arrhythmias, and endstage pulmonary disease) was associated with less screening mammography and later stage at diagnosis (OR = 1.3, 95% CI: 1.2-1.4) ( Table 3) . 76 Studies relating comorbidity to breast cancer screening have had mixed results, showing either increased or decreased risk of late-stage disease according to comorbidity burden. 76, 86 Impact of comorbidity on choice of treatment As shown in Table 1 , surgical management steadily declines with increasing comorbidity regardless of cancer site and disease stage. Berglund et al 38 found that the OR of no surgery was 1.88 (95% CI: 1.65-2.14) among breast cancer patients with a CCI score of 1, and 3.01 (95% CI: 2.67-3.41) among those with a CCI score $2, compared with patients without comorbidity. In a population-based cohort study conducted in Northern Denmark, Iversen et al 5 found that 83.8% of colon cancer patients with a CCI score of 0 undergo surgical resection, compared with 77.7% of patients with CCI scores of 1 or 2 and 63.2% of patients with a CCI score $3. Similarly, other studies have reported 25%-58% lower odds of surgical resection in lung cancer patients with severe comorbidity compared with patients without comorbidity. 11, 87, 88 90 compared with patients without comorbidity (Table 3 ). Other studies have reported 2-to 4-fold higher 30-day postoperative mortality rates in colon cancer patients with comorbidity compared to patients without comorbidities. 89, 91 Patients with comorbidities are less likely to receive any adjuvant chemotherapy, [92] [93] [94] [95] [96] [97] [98] [99] more likely to receive a reduced Table 3 Results of selected studies on the association between comorbidity and cancer stage at diagnosis 94 However, in another US study, colon cancer patients with comorbidity were less likely to receive chemotherapy, whether or not they consulted an oncologist (Table 1) . 95 Presence of comorbidity has also been associated with increased time from cancer detection to surgical resection or initiation of chemotherapy or radiotherapy. 88, 95, 104, 106, 107 The reasons for this remain unknown. There are few data on the impact of comorbidity on risk of complications after chemotherapy and radiation therapy. Grønberg et al 10 found that lung cancer patients with severe comorbidity were more likely than lung cancer patients without comorbidity to develop thrombocytopenia (46% vs 36%) or febrile neutropenia (12% vs 5%) or to die of neutropenic infection (3% vs 0.%) following chemotherapy treatment. Conversely, Gross et al 108 found that risk of hospitalization attributable to chemotherapy treatment was lower among colon cancer patients with COPD, chronic heart failure, or diabetes, compared with patients without these conditions ( Table 1) .
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Impact of comorbidity on health care-related factors
Treatment in specialized medical centers or by a high-volume surgeon has been associated with improved treatment and survival. [109] [110] [111] [112] [113] [114] However, there are very few studies on the prognostic impact of receiving high-volume-cancer-center care and highly specialized treatment in relation to comorbidity. A US study of 211,084 patients with lung, breast, colorectal, and prostate cancer found that patients treated at National Cancer Institute-designated cancer centers had lower mortality than patients treated at volume-matched hospitals across all levels of comorbidity . 111 Furthermore, while some studies have shown a social gradient in access to specialized cancer care, 114, 115 few studies have examined potential disparities in access to specialized care among patients with comorbidities.
To better understand the observed underutilization of treatment by age and comorbidity, a number of studies have explored physician and patient perspectives regarding the decision to use adjuvant chemotherapy. 105, [116] [117] [118] [119] It has been found that 24%-70% of cancer patients with comorbidity are not treated according to guidelines. 105, 118, [120] [121] [122] In a US national survey of surgeons and medical oncologists caring for patients with colorectal cancer, physicians agreed with guidelines recommending adjuvant chemotherapy for young, otherwise healthy patients with stage III colon cancer, but differed widely on recommendations for patients with comorbid illnesses. 119 Comorbidity is the most frequent reason for nonreceipt of cancer treatment cited in the medical charts of patients with lung (68% of nontreated patients) and colorectal (47% of nontreated patients) cancer. 117, 118 To some extent, this finding probably reflects concern about toxicity in patients with comorbidity. Among patients with lung cancer, Gironés et al 123 recently showed that withholding treatment was associated with factors such as poor health, advanced age, depression, and dementia, but not related to symptoms at diagnosis or cancer stage.
Physicians' motivations and treatment barriers are also influenced by age, race, and education level. Studies have shown that duration of consultations and amount of information provided to patients increases with higher education levels. [124] [125] [126] While patient perceptions and preferences play a role in treatment decisions and outcomes, the treating physician's recommendation has been found to be a major determinant of patients' preferences for chemotherapy. 127, 128 It remains unclear whether patient preferences differ according to level of comorbidity.
Influence of comorbidity on treatment regimen completion
Patients with comorbidities may be compromised in their ability to comply with treatment regimens or to tolerate their side effects. In a US cohort study of 3,733 colon cancer patients aged $65 years with records in the linked SEER-Medicare dataset during 1995-1999, comorbidity was associated with lower odds of completing adjuvant chemotherapy (adjusted ORs were 0.75 [95% CI: 0.60-0.97] for patients with one comorbidity and 0.62 [95% CI: 0.46-0.84] for patients with .1 comorbidity) compared with patients without comorbidity. 129 Several other studies have also shown that comorbidity is associated with decreased likelihood of completing chemotherapy treatment among patients with colon, 1, 102, 108 breast, 100 and lung cancer 10 (Table 1) . However, none of these studies examined whether failure to complete submit your manuscript | www.dovepress.com Dovepress Dovepress chemotherapy was related to poorer adherence or to level of side effects. Many studies of women with early-stage breast cancer, based on pharmacy, medical, and health insurance data, have reported high rates of discontinuation of adjuvant tamoxifen, ranging from 35%-51% during study periods of 3.5-5 years. [130] [131] [132] [133] Patient refusal reportedly accounts for a third of occurrences of treatment underuse, 134 and comorbidity has been identified as a predictor of discontinuation and nonadherence to regimens of tamoxifen and aromatase inhibitors. 132, 133 However, a very recent German cohort study of 12,412 women with breast cancer, among whom 7,312 were treated with tamoxifen, demonstrated lower rates of tamoxifen discontinuation among patients with diabetes 
Methodological considerations
Several methodological concerns must be considered when evaluating the summary evidence from the studies reviewed above. This review is not a systematic review. A research librarian assisted our searches, but we did not use explicit predefined criteria to select the articles included. Thus, our study selection was subjective and we may have missed relevant papers. The studies included were heterogeneous and included vastly different patient populations (Tables 1-3) . Moreover, many were designed as predictive studies and included a wide range of potential prognostic factors besides comorbidity in regression models. Some studies also included variables such as patient performance status (activities of daily living), 136 which may constitute an intermediate variable in the causal path from comorbidity to cancer survival. Adjusting for patient performance status thus may weaken the prognostic impact of comorbidity. A further challenge in summarizing the effect of comorbidity on cancer survival was inconsistent definitions of comorbidity. Comorbidity was measured in different ways in the studies under review, referring either to one specific disease or aggregation of several diseases using an index. Moreover, indices varied from general comorbidity measures to disease-specific measures. Most studies aggregated comorbidity into a comorbidity index (most frequently the CCI) ( Table 1 ) with little consideration of how specific conditions affected outcomes. Although shown repeatedly to be a valid prognostic predictor, the CCI itself is based on simple assumptions about mortality risk when various conditions co-occur. In addition, most studies collapsed the CCI score of above a certain threshold into a single open-ended category (eg, 0, 1-2, and $3) to improve comprehension and the statistical efficacy of the analysis Is the negative prognostic impact of comorbidity attributable to comorbidity-related deaths or does comorbidity also influence cancer-specific mortality?
How is tumor biology influenced by comorbidity?
How much of the negative prognostic impact of comorbidity is explained by differences in socioeconomic position, lifestyle, and social support?
Is comorbidity associated with less access to specialized care? Does treatment at increasingly specialized cancer centers improve cancer survival mainly in patients without severe comorbidity?
Are apparent disparities in cancer treatment among patients with comorbidity related to physician recommendations, patients' preferences, and/or decreased compliance?
Is comorbidity associated with higher risk of cancer treatment toxicity, given the limited participation of patients with comorbidity in randomized clinical trials?
How do individual comorbidities -alone and in combination -impact cancer patients' clinical courses? Does the prognostic effect of specific comorbidities vary according to cancer type?
How do duration and severity of comorbidity influence cancer prognosis?
How is comorbidity most accurately measured in cancer patients? 
23
The impact of comorbidity on cancer survival (the prevalence of patients with high CCI scores is low in most study populations). The effect of the combined category is a weighted average of the individual scores. 23 Analyses based on individual comorbid diseases would avoid these assumptions but are difficult to conduct, as they require much larger cohorts to identify subgroups with specific conditions of sufficient size. 137 It must also be noted that virtually none of the studies under review examined the impact of duration and/or severity of comorbidity on cancer prognosis.
Most studies in our review were based on analyses of population-based cancer registry data linked with administrative data. Such data are generally adequate for determining prevalence of comorbidity and survival outcomes, but generally provide limited information on treatment delivery or patient tolerance for treatment regimens. Furthermore, studies relying on such databases may miss important comorbidities, underestimate their severity, or fail to address confounding factors such as smoking and other lifestyle factors. Thus, to improve research on comorbidity, studies should include information from different data sources (ie, administrative data, chart review, prescription records, and records of general practitioners) to provide more information on level and severity of comorbidity.
Conclusion
Despite increasing recognition of the impact of comorbid illnesses on the prognosis of cancer patients, challenges remain. A large number of studies reported suboptimal treatment among patients with comorbidity across tumor sites and stages of disease. However, because most studies examined diagnosis, treatment, physician and/or patient preferences, but not all factors, it is unclear whether suboptimal cancer treatment reflects appropriate consideration of increased risk of toxicity due to comorbid illness, patient preferences, lower quality of clinical care, or poor adherence. Consequently, a number of questions remain unanswered about the relationship between comorbidity and cancer outcome (Figure 2 ). To adequately address these questions, studies are needed that elucidate whether comorbidity in general or only specific diseases or disease combinations are associated with poorer survival. Thus, studies with a more specific focus should be undertaken, including those that address the impact of an individual comorbidity on treatment provided to a homogenous population of cancer patients (ie, with comparable stage and tumor type). 
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